Publications by authors named "Naomi Mescall"
Background: To report on the implementation and outcomes of a virtual ward established for the management of mpox during the 2022 outbreak, we conducted a 2-center, observational, cross-sectional study over a 3-month period.
Methods: All patients aged ≥17 years with laboratory polymerase chain reaction-confirmed monkeypox virus managed between 14 May and 15 August 2022, at the Hospital for Tropical Diseases at University College London Hospitals National Health Service (NHS) Foundation Trust and sexual health services at Central North and West London NHS Foundation Trust, were included. Main outcomes included the proportion of patients managed exclusively on the virtual ward, proportion of patients requiring inpatient admission, proportion of patients with human immunodeficiency virus, and duration of lesion reepithelialization.
Article Synopsis
- - The study aimed to analyze real-world treatment persistence rates of disease-modifying therapies (DMTs) for individuals with multiple sclerosis (MS), examining factors that lead to discontinuation of these treatments.
- - Data from 4,366 patients with relapse-onset MS were collected from 13 specialist centers in the UK, finding a median persistence of 4.3 years on any DMT, with adverse events and lack of efficacy being the top reasons for stopping treatment.
- - Results indicated that immune reconstituting therapies like alemtuzumab may provide more prolonged DMT options compared to traditional therapies, emphasizing the importance of understanding DMT persistence for better treatment strategies.